Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $564 from $516 and keeps an Overweight rating on the shares after having hosted a lab tour and analyst meeting with the company’s CEO and kidney disease program leads. The firm refreshed its model following the recent pricing disclosure for Otsuka’s Voyxact as it raises its annual WAC price estimate for pipeline drugs Pove to $390,000 from $250,000.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Positioned for Blockbuster Success in Rare Disease Market with Strong Renal Franchise and Promising Clinical Data
- SPY ETF Daily Update, 12/3/2025
- Midday Fly By: Anthropic starts work on IPO, Marvell reports Q3 beat
- Oracle initiated, Uber upgraded: Wall Street’s top analyst calls
- Vertex upgraded to Overweight from Equal Weight at Morgan Stanley